(Q45296870)

11 December 2017

Phase II trial of fenretinide in advanced renal carcinoma (English)

1 reference

11 December 2017

phase II clinical trial

0 references

author name string

Ulka Vaishampayan

1

1 reference

11 December 2017

Lance K Heilbrun

2

1 reference

11 December 2017

Ralph E Parchment

3

1 reference

11 December 2017

Vikash Jain

4

1 reference

11 December 2017

James Zwiebel

5

1 reference

11 December 2017

Ramesh R Boinpally

6

1 reference

11 December 2017

Patricia LoRusso

7

1 reference

11 December 2017

Maha Hussain

8

1 reference

11 December 2017

1 March 2005

1 reference

Investigational New Drugs

11 December 2017

1 reference

11 December 2017

23

1 reference

11 December 2017

2

1 reference

11 December 2017

179-185

1 reference

https://scigraph.springernature.com/pub.10.1007/s10637-005-5864-7

11 December 2017

0 references

cites work

Mediation of N-(4-hydoxyphenyl)retinamide-induced apoptosis in human cancer cells by different mechanisms.

1 reference

12 December 2020

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

12 December 2020

Tolerability of the synthetic retinoid Fenretinide (HPR)

1 reference

12 December 2020

Classical and novel retinoids: their targets in cancer therapy

1 reference

12 December 2020

Inhibition of proliferation and induction of apoptosis in cervical carcinoma cells by retinoids: implications for chemoprevention

1 reference

12 December 2020

Regulation of apoptosis induced by the retinoid N-(4-hydroxyphenyl) retinamide and effect of deregulated bcl-2.

1 reference

12 December 2020

One-sample multiple testing procedure for phase II clinical trials

1 reference

12 December 2020

Differential effects of retinoic acid (RA) and N-(4-hydroxyphenyl) retinamide (4-HPR) on cell growth, induction of differentiation, and changes in p34cdc2, Bcl-2, and actin expression in the human promyelocytic HL-60 leukemic cells

1 reference

12 December 2020

N-(4-hydroxyphenyl)retinamide inhibits retinoblastoma growth through reactive oxygen species-mediated cell death

1 reference

12 December 2020

Plasma retinol level reduction by the synthetic retinoid fenretinide: a one year follow-up study of breast cancer patients

1 reference

12 December 2020

Synergistic anti-tumor effect of 13-cRA and IFN-alpha/beta in mouse renal cell carcinoma.

1 reference

12 December 2020

N-(4-hydroxyphenyl)retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid

1 reference

12 December 2020

Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma.

1 reference

12 December 2020

Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro

1 reference

12 December 2020

Safety of the synthetic retinoid fenretinide: long-term results from a controlled clinical trial for the prevention of contralateral breast cancer

1 reference

12 December 2020

Growth inhibition and induction of apoptosis by fenretinide in small-cell lung cancer cell lines.

1 reference

12 December 2020

Clinical applications of retinoids in cancer medicine.

1 reference

12 December 2020

N-(4-hydroxyphenyl)retinamide: a Potent Inducer of Apoptosis in Human Neuroblastoma Cells

1 reference

12 December 2020

Effect of 4-hydroxyphenylretinamide and retinoic acid on proliferation and cell cycle of cultured human breast cancer cells

1 reference

12 December 2020

Chemoprevention of breast cancer with fenretinide

1 reference

12 December 2020

Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma.

1 reference

12 December 2020

Interaction of retinoic acid and interferon in renal cancer cell lines

1 reference

12 December 2020

All-trans-retinoic acid in acute promyelocytic leukemia

1 reference

12 December 2020

Fenretinide (4-HPR) in chemoprevention of oral leukoplakia

1 reference

12 December 2020

10.1007/S10637-005-5864-7

Identifiers

DOI

1 reference

Dimensions Publication ID

11 December 2017

0 references

1 reference